New model systems provide insights into Myc-induced transformation

Oncogene

Volumn 30, Issue 34, 2011, Pages 3727-3734

  Wasylishen, A R ^a,b   Stojanova, A ^a,b   Oliveri, S ^a,b   Rust, A C ^a,b   Schimmer, A D ^a,b   Penn, L Z ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

cellular transformation; hTERT; Myc; simian virus 40; structure function

Indexed keywords

MYC PROTEIN; ONCOPROTEIN;

AMINO TERMINAL SEQUENCE; ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; FIBROBLAST; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL;

CELL LINE, TRANSFORMED; CELL TRANSFORMATION, NEOPLASTIC; GENES, MYC; HUMANS; MODELS, GENETIC;

RODENTIA; SIMIAN VIRUS 40;

EID: 80052039605     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.88     Document Type: Article

References (38)

1. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S et al. (1985). The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318: 533-538. (Pubitemid 16173038)
2. Bahram F, von der Lehr N, Cetinkaya C, Larsson LG. (2000). c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood 95: 2104-2110. (Pubitemid 30151652)
3. Bhatia K, Huppi K, Spangler G, Siwarski D, Iyer R, Magrath I. (1993). Point mutations in the c-Myc transactivation domain are common in Burkitt0s lymphoma and mouse plasmacytomas. Nat Genet 5: 56-61. (Pubitemid 23261519)
4. Breit S, Schwab M. (1989). Suppression of MYC by high expression of NMYC in human neuroblastoma cells. J Neurosci Res 24: 21-28. (Pubitemid 19262382)
5. Callus BA, Ekert PG, Heraud JE, Jabbour AM, Kotevski A, Vince JE et al. (2008). Cytoplasmic p53 is not required for PUMA-induced apoptosis. Cell Death Differ 15: 213-215. (Pubitemid 350286189)
6. Chang DW, Claassen GF, Hann SR, Cole MD. (2000). The c-Myc transactivation domain is a direct modulator of apoptotic versus proliferative signals. Mol Cell Biol 20: 4309-4319. (Pubitemid 30346625)
7. Chen W, Hahn WC. (2003). SV40 early region oncoproteins and human cell transformation. Histol Histopathol 18: 541-550. (Pubitemid 36362072)
8. Cleveland JL, Huleihel M, Bressler P, Siebenlist U, Akiyama L, Eisenman RN et al. (1988). Negative regulation of c-myc transcription involves myc family proteins. Oncog Res 3: 357-375. (Pubitemid 19049219)
9. Conzen SD, Gottlob K, Kandel ES, Khanduri P, Wagner AJ, O'Leary M et al. (2000). Induction of cell cycle progression and acceleration of apoptosis are two separable functions of c-Myc: transrepression correlates with acceleration of apoptosis. Mol Cell Biol 20: 6008-6018. (Pubitemid 30613049)
10. Cowling VH, D'Cruz CM, Chodosh LA, Cole MD. (2007). c-Myc transforms human mammary epithelial cells through repression of the Wnt inhibitors DKK1 and SFRP1. Mol Cell Biol 27: 5135-5146. (Pubitemid 47068288)
11. Debnath J, Muthuswamy SK, Brugge JS. (2003). Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 30: 256-268. (Pubitemid 36677560)
12. Drayton S, Peters G. (2002). Immortalisation and transformation revisited. Curr Opin Genet Dev 12: 98-104. (Pubitemid 34094997)
13. Gregory MA, Qi Y, Hann SR. (2003). Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization. J Biol Chem 278: 51606-51612. (Pubitemid 38020405)
14. Gustafson WC, Weiss WA. (2010). Myc proteins as therapeutic targets. Oncogene 29: 1249-1259.
15. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. (1999). Creation of human tumour cells with defined genetic elements. Nature 400: 464-468. (Pubitemid 29361801)
16. Hemann MT, Bric A, Teruya-Feldstein J, Herbst A, Nilsson JA, Cordon-Cardo C et al. (2005). Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 436: 807-811. (Pubitemid 41160633)
17. Herbst A, Hemann MT, Tworkowski KA, Salghetti SE, Lowe SW, Tansey WP. (2005). A conserved element in Myc that negatively regulates its proapoptotic activity. EMBO Rep 6: 177-183. (Pubitemid 40309416)
18. Kim SS, Shago M, Kaustov L, Boutros PC, Clendening JW, Sheng Y et al. (2007). CUL7 is a novel antiapoptotic oncogene. Cancer Res 67: 9616-9622. (Pubitemid 47621206)
19. Kuttler F, Ame P, Clark H, Haughey C, Mougin C, Cahn JY et al. (2001). c-myc box II mutations in Burkitt0s lymphoma-derived alleles reduce cell-transformation activity and lower response to broad apoptotic stimuli. Oncogene 20: 6084-6094. (Pubitemid 32955051)
20. Land H, Parada LF, Weinberg RA. (1983). Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 304: 596-602. (Pubitemid 13035496)
21. Landay M, Oster SK, Khosravi F, Grove LE, Yin X, Sedivy J et al. (2000). Promotion of growth and apoptosis in c-myc nullizygous fibroblasts by other members of the myc oncoprotein family. Cell Death Differ 7: 697-705. (Pubitemid 30599250)
22. Langdon WY, Harris AW, Cory S, Adams JM. (1986). The c-myc oncogene perturbs B lymphocyte development in E-mu-myc transgenic mice. Cell 47: 11-18. (Pubitemid 17181528)
23. Lutz W, Stohr M, Schurmann J, Wenzel A, Lohr A, Schwab M. (1996). Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene 13: 803-812. (Pubitemid 26312908)
24. Malynn BA, de Alboran IM, O'Hagan RC, Bronson R, Davidson L, DePinho RA et al. (2000). N-myc can functionally replace c-myc in murine development, cellular growth, and differentiation. Genes Dev 14: 1390-1399. (Pubitemid 30397082)
25. McMahon SB, Van Buskirk HA, Dugan KA, Copeland TD, Cole MD. (1998). The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins. Cell 94: 363-374. (Pubitemid 28376080)
26. Meyer N, Penn LZ. (2008). Reflecting on 25 years with MYC. Nat Rev Cancer 8: 976-990.
27. Oster SK, Mao DY, Kennedy J, Penn LZ. (2003). Functional analysis of the N-terminal domain of the Myc oncoprotein. Oncogene 22: 1998-2010. (Pubitemid 36523637)
28. Penn LJ, Brooks MW, Laufer EM, Land H. (1990). Negative autoregulation of c-myc transcription. EMBO J 9: 1113-1121.
29. Prowse KR, Greider CW. (1995). Developmental and tissue-specific regulation of mouse telomerase and telomere length. Proc Natl Acad Sci USA 92: 4818-4822.
30. Schwab M. (2004). MYCN in neuronal tumours. Cancer Lett 204: 179-187. (Pubitemid 38167721)
31. Soule HD, Maloney TM, Wolman SR, Peterson Jr WD, Brenz R, McGrath CM et al. (1990). Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 50: 6075-6086. (Pubitemid 20331424)
32. Spotts GD, Patel SV, Xiao Q, Hann SR. (1997). Identification of downstream-initiated c-Myc proteins which are dominant-negative inhibitors of transactivation by full-length c-Myc proteins. Mol Cell Biol 17: 1459-1468. (Pubitemid 27097375)
33. Stewart TA, Pattengale PK, Leder P. (1984). Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes. Cell 38: 627-637. (Pubitemid 15176093)
34. Stone J, de Lange T, Ramsay G, Jakobovits E, Bishop JM, Varmus H et al. (1987). Definition of regions in human c-myc that are involved in transformation and nuclear localization. Mol Cell Biol 7: 1697-1709. (Pubitemid 17059163)
35. Vervoorts J, Luscher-Firzlaff J, Luscher B. (2006). The ins and outs of MYC regulation by posttranslational mechanisms. J Biol Chem 281: 34725-34729. (Pubitemid 46036511)
36. Wei W, Jobling WA, Chen W, Hahn WC, Sedivy JM. (2003). Abolition of cyclin-dependent kinase inhibitor p16Ink4a and p21Cip1/Waf1 functions permits Ras-induced anchorage-independent growth in telomerase-immortalized human fibroblasts. Mol Cell Biol 23: 2859-2870. (Pubitemid 36403083)
37. Wood MA, McMahon SB, Cole MD. (2000). An ATPase/helicase complex is an essential cofactor for oncogenic transformation by c-Myc. Mol Cell 5: 321-330. (Pubitemid 30628090)
38. Wu J, Wong WW, Khosravi F, Minden MD, Penn LZ. (2004). Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer Res 64: 6461-6468. (Pubitemid 39297901)